<DOC>
	<DOC>NCT01401075</DOC>
	<brief_summary>Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUMÂ® Quercus, aVQ) in patients with gastric cancer receiving oral chemotherapy.</brief_summary>
	<brief_title>RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Viscum album peptide</mesh_term>
	<mesh_term>Doxifluridine</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<criteria>postoperative UICC stage Ib/II gastric carcinoma indication for oral chemotherapy with doxifluridine ECOG performance status 0 or 1 normal liver and kidney function inability to answer the QoL scales concomitant therapy with steroids or biological response modifiers individual hypersensitivity to mistletoe preparations pregnancy or lactating participation in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Quality of Life</keyword>
	<keyword>QoL</keyword>
	<keyword>EORTC QLQ-C30</keyword>
	<keyword>EORTC QLQ-STO22</keyword>
	<keyword>5-FU</keyword>
	<keyword>Viscum album</keyword>
</DOC>